• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Between Headwinds and Horizons

Biotech Letter

In the pursuit of safe, sustainable, and substantial dividend yields, my quest often leads me to the realm of dividend aristocrats.

A particular entity that has caught my interest is the biotech behemoth Amgen Inc. (AMGN).

Although the company has been treading on a rocky path, with its shares plunging below their previous highs and year-to-date performance, it continues to pique my curiosity. After all, this downward trend does present a silver lining.

It unlocks an investment opportunity in the form of a record 3.9% dividend yield that AMGN currently offers, with its strong business performance and anticipated robust free cash flow countering any valuation concerns.

Still, investing in biotech is more than just a mere bet on a company's innovative prowess. It's also a gamble on the company’s skill to maneuver through the labyrinth of policy interventions.

Recent headlines talk about AMGN's ongoing battles, with a plethora of challenges leading investors to remain on the sidelines.

The IRS' quest for billions in back taxes from the company, the Federal Trade Commission's move to halt its massive acquisition of Horizon Therapeutics (HZNP), and a Supreme Court ruling against Amgen in a crucial patent case are just some of the headwinds the company faces.

Amidst these, the impending patent cliff hangs like a Damocles sword, with several of its blockbuster drugs, such as Enbrel and Otezla, likely to witness revenue shrinkage owing to patent expirations and intensifying competition.

Yet, despite the grim scenario, there are silver linings.

AMGN's proposed acquisition of Horizon Therapeutics was driven by the latter's key drug, Tepezza. However, declining sales have put the future of this acquisition into question.

Despite the swirling questions, AMGN remains confident about the eventual success of the Horizon deal. Its leadership foresees no anti-competitive barriers obstructing this merger and anticipates a positive outcome from the FTC hearing later this year.

In relation to Tepezza, the company underscores the synergistic benefits post-merger that can enhance the drug's value. Notably, the larger scale and international presence of AMGN, coupled with its manufacturing expertise, will give a significant boost to Tepezza's sales.

The company has other acquisition options if the Horizon deal hits a roadblock.

Potential targets could be Intellia Therapeutics (NTLA) and Rhythm Pharmaceuticals (RYTM), both of which offer great value at the current price point. The addition of these companies could enhance AMGN's portfolio with promising therapies for rare genetic disorders while providing a potentially novel gene-editing technology.

Furthermore, AMGN is upping the ante in its biosimilar initiatives, viewing its protein manufacturing and clinical development capabilities as its unique strengths. An excellent example is the successful launch of its recent biosimilar, AMJEVITA. Moreover, the company’s plans for more candidates attest to this optimism.

Meanwhile, AMGN's efforts are showing results. Despite a dip in the first quarter of 2023’s net income due to higher expenses, there was a robust volume growth powered by several tailwinds, including the fading impact of COVID. This, along with record sales of key drugs, lends the company confidence for the rest of the year and beyond.

The company also sees growth in international markets, especially in aging populations like Japan and China, and remains optimistic about its growth potential despite price erosion and competition.

On the dividends front, AMGN scores highly with its current yield of 3.9%, backed by a modest 46% payout ratio. Its impressive dividend growth record, coupled with anticipated free cash flow, makes it a promising candidate for dividend growth investors.

Overall, the company’s current stock price offers an attractive opportunity despite the challenges ahead. Given its current trajectory, it’s apparent that AMGN's track record of outperforming the market could very well repeat in the future, promising potentially lucrative returns for those who dare to navigate through the headwinds.

 

amgn

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2023-07-06 16:00:202023-07-09 23:41:54Between Headwinds and Horizons
You might also like
April 20, 2022
From Limping To Leaping
July 14, 2022
August 8, 2024
April 11, 2023
The Holy Grail of Diabetes

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Link to: July 6, 2023 Link to: July 6, 2023 July 6, 2023 Link to: July 6, 2023 Link to: July 6, 2023 July 6, 2023
Scroll to top